Massey researchers recognized with VCU distinguished faculty awards
VCU Massey Cancer Center’s director, Gordon Ginder, M.D., and Massey researcher, Thomas Eissenberg, Ph.D., were recognized with prestigious awards at Virginia Commonwealth University’s 2015 Opening Faculty Address and Convocation on Tuesday, August 18. Awards were presented to faculty members who have distinguished themselves and the university through their commitment to excellence, service, teaching and scholarship.
Massey researcher receives grant funding to support further pre-clinical testing of a promising neuroblastoma therapy
VCU Massey Cancer Center researcher Anthony Faber, Ph.D., was awarded a $250,000 grant from Alex’s Lemonade Stand Foundation to support further laboratory research to provide the validation needed to develop clinical trials to test a new therapy for neuroblastoma, the second deadliest cancer in children.
Novel model developed to predict nicotine emitted from e-cigarettes
VCU Massey Cancer Center researchers at the VCU Center for the Study of Tobacco Products (CSTP) have developed the first ever, evidence-based model that can predict with up to 90 percent accuracy the amount of nicotine emitted by an electronic cigarette (e-cigarette).
The researchers, working in collaboration with investigators at the American University of Beirut, The model predicted that higher voltage e-cigarette devices paired with high-concentration nicotine liquids could emit greater levels of the addictive substance than those of a traditional tobacco cigarette, depending on user puff duration.
Twitter chat on coping with cancer
Recently, the National Cancer Institute and the National Institutes of Mental Health co-hosted a Twitter chat on coping with cancer. The discussion focused on the psycho-social aspects of cancer for patients and caregivers across all age groups, and VCU Massey Cancer Center clinical health psychologist, Tamara Orr, Ph.D., M.S., L.C.P., PMHNP-BC, weighed in as the moderator posed a series of questions.
Massey opens clinical trial testing a combination of Viagra and chemo to treat advanced solid tumors
VCU Massey Cancer Center has developed and opened a Phase 1 clinical trial to study the effects of Viagra in combination with chemotherapy to treat patients with progressive, advanced solid tumors. The trial is a result of previous research conducted at Massey by a group of researchers including physician-scientist Andrew Poklepovic, M.D., who is the leading the trial as its principal investigator. Their research demonstrated that regorafenib (trade name Stivarga), a type of chemotherapy, interacts with Viagra (generic name sildenafil), a medication originally developed for erectile dysfunction, to kill tumor cells significantly better than regorafenib alone.